Literature DB >> 26751964

Hypertensive/Microvascular Disease and COPD: a Case Control Study.

Sky K H Chew1, Deb Colville, Piers Canty, Anastasia Hutchinson, Alex Wong, Vi Luong, Tien Y Wong, Christine McDonald, Judy Savige.   

Abstract

BACKGROUND/AIMS: This study tested the hypothesis that individuals with chronic obstructive pulmonary disease (COPD) have more small vessel disease and more severe disease than an age- and gender- matched hospital patient comparison group.
METHODS: This was a single centre, case-control study of 151 individuals with COPD (FEV1/VC) < 0.7 recruited consecutively immediately after respiratory function tests at a Melbourne teaching hospital over a 4 month period in 2010. Controls were individuals with normal respiratory function tests recruited contemporaneously from the same centre. Retinal images were obtained with a nonmydriatic camera (KOWA or Canon CR5-45NM), deidentiifed and graded by two trained graders for microvascular retinopathy (Wong and Mitchell classification), and vessel calibre using a computer-assisted method and Knudtson's modification of the Parr-Hubbard formula. Differences in microvascular retinopathy and vessel calibre between COPD patients and the comparison group were examined using Fisher's exact test or the t test (StataCorp, Texas).
RESULTS: Patients with COPD had more microvascular retinopathy (121, 80% and 76, 50%; OR 3.98, 95%CI 2.39 to 6.64) and more severe disease (42, 28% and 18, 12%; OR 2.85, 95% CI 1.55 to 5.23) than other hospital patients. COPD remained an independent determinant of microvascular retinopathy (OR 4.56, 95%CI 2.49 to 8.36) after adjusting for gender, hypertension, smoking, and diabetes duration. Retinal arterioles and venules were wider in patients with COPD than other hospital patients (mean difference +6.5 µm, 95% confidence interval 1.4 to 11.6; and +17.4 µm, 95%CI 9.4 to 25.5, respectively). Larger venules were more common in younger individuals (+0.6 µm, 0.1 to 1.17) with more cigarette exposure (+0.3 µm, 0.2 to 0.5) or a lower serum albumin (+23.0 µm, 6.0 to 40.0). Venular calibre was not different in current and former smokers (p=0.77). There were trends for venules to be larger with more severe COPD (lower FEV1/VC, p=0.09) and with CT-demonstrated emphysema (p=0.06).
CONCLUSIONS: Hypertensive/microvascular disease is more common and more severe in patients with COPD. This is likely to contribute to the associated increase in cardiac risk.
© 2016 The Author(s) Published by S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2016        PMID: 26751964     DOI: 10.1159/000368544

Source DB:  PubMed          Journal:  Kidney Blood Press Res        ISSN: 1420-4096            Impact factor:   2.687


  5 in total

1.  Treatment variation related to comorbidity and complications in type 2 diabetes: A real world analysis.

Authors:  Yeon Young Cho; Sung-Il Cho
Journal:  Medicine (Baltimore)       Date:  2018-09       Impact factor: 1.817

2.  Structural analysis of retinal blood vessels in patients with COPD during a pulmonary rehabilitation program.

Authors:  Anouk W Vaes; Martijn A Spruit; Karel Van Keer; João Barbosa-Breda; Emiel F M Wouters; Frits M E Franssen; Jan Theunis; Patrick De Boever
Journal:  Sci Rep       Date:  2020-01-08       Impact factor: 4.379

3.  Simple non-mydriatic retinal photography is feasible and demonstrates retinal microvascular dilation in Chronic Obstructive Pulmonary Disease (COPD).

Authors:  G J McKay; R V McCarter; R E Hogg; D H Higbee; M-P K Bajaj; D R Burrage; S Ruickbie; E H Baker; P W Jones; J W Dodd
Journal:  PLoS One       Date:  2020-01-10       Impact factor: 3.240

4.  Retinal small vessel dilatation in the systemic inflammatory response to surgery.

Authors:  Alexander Grogan; Karen Barclay; Deb Colville; Lauren Hodgson; Judy Savige
Journal:  Sci Rep       Date:  2022-08-02       Impact factor: 4.996

5.  Obstructive sleep apnea, chronic obstructive pulmonary disease and hypertensive microvascular disease: a cross-sectional observational cohort study.

Authors:  Sky Chew; Deb Colville; Anastasia Hutchinson; Piers Canty; Lauren Hodgson; Judy Savige
Journal:  Sci Rep       Date:  2022-08-03       Impact factor: 4.996

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.